Dr. Will Gibson and Dr. C. Michael Gibson discuss how p53 was once considered an undruggable target for cancer therapy.
A new article in the NEJM raises hope that there may be a path forward. Dr. Will Gibson, an oncologist at […]
Clinical Trial Results
Search
Dr. Mike Sharma and Dr. C. Michael Gibson discuss the results of the phase III OCEANIC-STROKE Trial
In secondary stroke prevention the Factor Xi inhibitor Asundexian reduced the risk of recurrent ischemic stroke at 1 year by […]
Dr. Nicole Cyrille Superville and Dr. C. Michael Gibson discuss: Demographic Disparities in Tafamidis Treatment and Clinical Outcomes Across the United States
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.
Dr. Sandesh Dev and Dr. C. Michael Gibson discuss: Geographic Disparities in Transthyretin Amyloid Cardiomyopathy Prevalence in United States Veterans.
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.
Dr. Jim Januzzi and Dr. C. Michael Gibson discuss: Acoramidis Lowers NT-proBNP in a Larger Proportion of ATTRibute-CM Study Participants With Transthyretin Amyloid.
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.